{"filing":{"accession_number":"0001628280-26-048922","cik":"0002007191","ticker":"TLPPF","company_name":"Telix Pharmaceuticals Ltd","form":"6-K","filing_date":"2026-07-21","report_date":null,"primary_document":"telix-6kforq22026tradingup.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/2007191/000162828026048922/telix-6kforq22026tradingup.htm"},"events":[{"id":18948,"run_id":17048,"accession_number":"0001628280-26-048922","anchor_item_number":"EX-99.1","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"This exhibit is a quarterly earnings release announcing Q2 2026 financial results for Telix Pharmaceuticals. The document discloses \"Group revenue of US$247 million, up 7% quarter-over-quarter and up 21% year-over-year\" and provides FY 2026 revenue guidance of \"in excess of US$1 billion.\" The release includes detailed financial performance metrics, business unit results, and forward-looking guidance typical of a quarterly earnings announcement. Material to investors assessing the company's commercial performance and trajectory.","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-07-21","form":"6-K","submitted_at":null,"items":[{"id":17911,"accession_number":"0001628280-26-048922","item_number":"EX-99.1","item_title":"a20260721telixq2revenueu.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a quarterly earnings release announcing Q2 2026 financial results for Telix Pharmaceuticals. The document discloses \"Group revenue of US$247 million, up 7% quarter-over-quarter and up 21% year-over-year\" and provides FY 2026 revenue guidance of \"in excess of US$1 billion.\" The release includes detailed financial performance metrics, business unit results, and forward-looking guidance typical of a quarterly earnings announcement. Material to investors assessing the company's commercial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:06:39.365955+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":17911,"accession_number":"0001628280-26-048922","item_number":"EX-99.1","item_title":"a20260721telixq2revenueu.htm","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"This exhibit is a quarterly earnings release announcing Q2 2026 financial results for Telix Pharmaceuticals. The document discloses \"Group revenue of US$247 million, up 7% quarter-over-quarter and up 21% year-over-year\" and provides FY 2026 revenue guidance of \"in excess of US$1 billion.\" The release includes detailed financial performance metrics, business unit results, and forward-looking guidance typical of a quarterly earnings announcement. Material to investors assessing the company's commercial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-21T11:06:39.365955+00:00","company_name":"Telix Pharmaceuticals Ltd","ticker":"TLPPF","filing_date":"2026-07-21"}]}